Skip to main content
OpenTrials
Completed

NCT Number: NCT04984941

Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients

One hundred patients were enrolled, based on sensitization and doctor-diagnosed allergy to HDM. Questionnaires were administered to document demographic and clinical characteristics. Serum IgE reactivity toDermatophagoides pteronyssinus (Dp) extract, Der p 1, Der p 2 and Der p 10 was measured by ImmunoCAP.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Allergic Rhinitis Atopic Dermatitis Bronchial Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Conjunctival Diseases Conjunctivitis Dermatitis Dermatitis, Atopic Eye Diseases Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

3 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Second Affiliated Hospital，School of Medicine，Zhejiang University

Hangzhou, Zhejiang, China

About this study

Background: The role of specific IgE (sIgE) against Der p 1and Der p 2 in Chinese patients with house dust mite (HDM)allergy has not yet been well investigated.Methods: One hundred patients were enrolled, based on sensitization and doctor-diagnosed allergy to HDM. Questionnaires were administered to document demographic and clinical characteristics. Serum IgE reactivity toDermatophagoides pteronyssinus (Dp) extract, Der p 1, Der p 2 and Der p 10 was measured by ImmunoCAP.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HDM-allergic patients reporting allergic rhinitis, conjunctivitis, asthma and/or atopic dermatitis and who had never undergone immunotherapy, were enrolled if they were sensitized to Dp as judged by ImmunoCAP ( ≥ 1 kU/l) and/or skin reaction index (SRI)by skin-prick test (SPT, a wheal diameter ≥ 0.5 mm).

Exclusion criteria

  • Patients who refused to participate in the study.

Treatment and study plan

Primary outcomes

  1. Demographic Characteristics

    Time frame: 1 year

    Describe the patient's basic information in detail, including age, gender, family history, etc

  2. Der p 1 Serum IgE

    Time frame: 1 year

    Prevalence of Der p 1 Serum IgE in HDM-Allergic Patients

  3. Der p 2 Serum IgE

    Time frame: 1 year

    Prevalence of Der p 2 Serum IgE in HDM-Allergic Patients

  4. Dp, Der p 1 and Der p 2

    Time frame: 1 year

    Relationship between Serum IgE Levels of Dp, Der p 1 and Der p 2

  5. Factors associated with specific IgE against Der p 1

    Time frame: 1 year

    Study the patient's basic information and identify factors that are clearly associated with specific IgE against Der p 1

  6. Factors associated with specific IgE against Der p 2

    Time frame: 1 year

    Study the patient's basic information and identify factors that are clearly associated with specific IgE against Der p 2

  7. the Number of Affected Organs

    Time frame: 1 year

    Association of Specific IgE Titers with the Number of Affected Organs

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Aug 2, 2021
Registry last updated
Aug 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.